Preclinical Alzheimer's disease: a systematic review of the cohorts underlying the concept

Abstract : Preclinical Alzheimer's disease (AD) is a relatively recent concept describing an entity characterized by the presence of a pathophysiological biomarker signature characteristic for AD in the absence of specific clinical symptoms. There is rising interest in the scientific community to define such an early target population mainly due to failures of all recent clinical trials despite evidence of biological effects on brain amyloidosis for some compounds. A conceptual framework has recently been proposed for this preclinical phase of AD. However, few data exist on this silent stage of AD. We performed a systematic review in order to investigate how the concept is defined across studies. The review highlights the substantial heterogeneity concerning the three main determinants of preclinical AD: " normal cognition " , " cognitive decline " and " AD pathophysiological signature ". We emphasize the need for a harmonized nomenclature of the preclinical AD concept and standardized population-based and case-control studies using unified operationalized criteria.
Document type :
Journal articles
Complete list of metadatas

https://hal.inria.fr/hal-01672859
Contributor : Stéphane Epelbaum <>
Submitted on : Wednesday, December 27, 2017 - 2:57:28 PM
Last modification on : Tuesday, April 30, 2019 - 3:42:58 PM

File

Epelbaum et al 2017 for HAL.pd...
Files produced by the author(s)

Identifiers

Citation

Stéphane Epelbaum, Rémy Genthon, Enrica Cavedo, Marie Habert, Foudil Lamari, et al.. Preclinical Alzheimer's disease: a systematic review of the cohorts underlying the concept. Alzheimer's and Dementia, Elsevier, 2017, 13 (4), pp.454-467. ⟨10.1016/j.jalz.2016.12.003⟩. ⟨hal-01672859⟩

Share

Metrics

Record views

293

Files downloads

552